Start SIP in
BIOCON
Access 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE on our charts.Performance
- Low
- ₹330
- High
- ₹341
- 52 Week Low
- ₹270
- 52 Week High
- ₹405
- Open Price₹341
- Previous Close₹341
- Volume2,162,491
Investment Returns
- Over 1 Month + 0.36%
- Over 3 Month + 3.29%
- Over 6 Month + 3.1%
- Over 1 Year + 8.29%
Smart Investing Starts Here Start SIP with Biocon for Steady Growth!
Biocon Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 39.5
- PEG Ratio
- -43.9
- Market Cap Cr
- 39,992
- P/B Ratio
- 1.9
- Average True Range
- 11.02
- EPS
- 7.83
- Dividend Yield
- 0.2
- MACD Signal
- 1.16
- RSI
- 49.78
- MFI
- 62.39
Biocon Financials
Biocon Technicals
EMA & SMA
-
- Bearish Moving Average 13
-
- Bullish Moving Average 3
- 20 Day
- ₹333.86
- 50 Day
- ₹334.98
- 100 Day
- ₹339.63
- 200 Day
- ₹337.94
Resistance and Support
- R3 349.53
- R2 345.07
- R1 339.08
- S1 328.63
- S2 324.17
- S3 318.18
Biocon Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-05-08 | Audited Results & Final Dividend | |
| 2025-04-23 | Others | Inter-alia, to consider 1. The proposal for Raising of funds by way of issue of equity shares or any other eligible securities, through one or more of the permissible modes, further public offer, etc. per share(10%)Final Dividend |
| 2025-04-04 | To consider Fund Raising | |
| 2025-01-30 | Quarterly Results & Others | To consider other business matters. per share(10%)Final Dividend |
| 2025-01-27 | Others | Inter-alia, to consider 1. Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis. per share(10%)Final Dividend |
Biocon F&O
About Biocon
Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bengaluru, India. The company has more than 16,545 employees as on March 2023. It focuses on all phases of the product cycle from researching to development and then introducing them to the market. They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies.
Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine) & so on.
View More- NSE Symbol
- BIOCON
- BSE Symbol
- 532523
- Managing Director & CEO
- Mr. Siddharth Mittal
- ISIN
- INE376G01013
Similar Stocks to Biocon
Biocon FAQs
Biocon share price is ₹333 As on 23 May, 2025 | 00:49
The Market Cap of Biocon is ₹39992 Cr As on 23 May, 2025 | 00:49
The P/E ratio of Biocon is 39.5 As on 23 May, 2025 | 00:49
The PB ratio of Biocon is 1.9 As on 23 May, 2025 | 00:49
Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.
Biocon Ltd. has declared 17 dividends since July 1, 2004.
The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.
The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.
The ROE of Biocon Limited is 9% which is fair but needs improvement.
Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.
According to the record analysis of moneyworks4me, Biocom limited is an average quality company.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.